APLT vs. CDMO, GTHX, RIGL, PBYI, PRTA, AMRX, DCPH, BHC, CPRX, and AMPH
Should you be buying Applied Therapeutics stock or one of its competitors? The main competitors of Applied Therapeutics include Avid Bioservices (CDMO), G1 Therapeutics (GTHX), Rigel Pharmaceuticals (RIGL), Puma Biotechnology (PBYI), Prothena (PRTA), Amneal Pharmaceuticals (AMRX), Deciphera Pharmaceuticals (DCPH), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical preparations" industry.
Avid Bioservices (NASDAQ:CDMO) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, community ranking, media sentiment, risk and dividends.
Applied Therapeutics has a net margin of 0.00% compared to Applied Therapeutics' net margin of -100.57%. Applied Therapeutics' return on equity of -11.27% beat Avid Bioservices' return on equity.
Applied Therapeutics has lower revenue, but higher earnings than Avid Bioservices. Avid Bioservices is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.
Avid Bioservices received 296 more outperform votes than Applied Therapeutics when rated by MarketBeat users. Likewise, 66.55% of users gave Avid Bioservices an outperform vote while only 56.69% of users gave Applied Therapeutics an outperform vote.
Avid Bioservices has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500.
97.2% of Avid Bioservices shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 2.4% of Avid Bioservices shares are owned by company insiders. Comparatively, 8.6% of Applied Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Avid Bioservices currently has a consensus target price of $12.67, suggesting a potential upside of 23.82%. Applied Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 110.73%. Given Avid Bioservices' stronger consensus rating and higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Avid Bioservices.
In the previous week, Applied Therapeutics had 1 more articles in the media than Avid Bioservices. MarketBeat recorded 3 mentions for Applied Therapeutics and 2 mentions for Avid Bioservices. Applied Therapeutics' average media sentiment score of 0.44 beat Avid Bioservices' score of 0.32 indicating that Avid Bioservices is being referred to more favorably in the media.
Summary
Applied Therapeutics beats Avid Bioservices on 12 of the 18 factors compared between the two stocks.
Get Applied Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Applied Therapeutics Competitors List
Related Companies and Tools
